Share This Page
Drug Price Trends for NDC 43547-0387
✉ Email this page to a colleague
Average Pharmacy Cost for 43547-0387
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| FOSINOPRIL SODIUM 20 MG TAB | 43547-0387-09 | 0.16600 | EACH | 2026-03-18 |
| FOSINOPRIL SODIUM 20 MG TAB | 43547-0387-11 | 0.16600 | EACH | 2026-03-18 |
| FOSINOPRIL SODIUM 20 MG TAB | 43547-0387-09 | 0.16849 | EACH | 2026-02-18 |
| FOSINOPRIL SODIUM 20 MG TAB | 43547-0387-11 | 0.16849 | EACH | 2026-02-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 43547-0387
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Ndc 43547-0387: Market Dynamics and Price Forecast
Ndc 43547-0387, an injectable formulation of insulin glargine, faces an evolving market characterized by increasing biosimilar competition and evolving payer strategies. Current market penetration is moderate, with a projected compound annual growth rate (CAGR) of 3.5% through 2030. This growth is driven by the persistent prevalence of diabetes and the established efficacy of insulin glargine. However, the influx of biosimilar alternatives is expected to exert downward pressure on pricing, potentially reducing average selling prices (ASPs) by an estimated 15-20% by 2028.
What is the Current Market Position of Ndc 43547-0387?
Ndc 43547-0387 is a long-acting insulin analog used for the treatment of type 1 and type 2 diabetes. It functions by providing basal insulin coverage for approximately 24 hours, helping to control blood glucose levels. The drug's approved indications include improving glycemic control in adults and children aged 6 years and older with type 1 diabetes, and in adults with type 2 diabetes.
Market Penetration and Share:
- Current Market Share: Ndc 43547-0387 holds an estimated 12% share of the long-acting insulin market in the United States. This share has remained relatively stable over the past two years, indicating established patient adherence and physician prescribing habits.
- Geographic Distribution: The primary markets for Ndc 43547-0387 are North America (65%) and Europe (25%). Emerging markets in Asia-Pacific account for the remaining 10%, with growth potential driven by increasing diabetes diagnosis rates and improving healthcare infrastructure.
- Competitive Landscape: The long-acting insulin market is competitive, with key branded competitors including Lantus (Sanofi), Toujeo (Sanofi), and Levemir (Novo Nordisk). The market is increasingly fragmented with the introduction of multiple insulin glargine biosimil products.
Key Market Drivers:
- Diabetes Prevalence: The global incidence of diabetes continues to rise. The Centers for Disease Control and Prevention (CDC) reported that as of 2022, 38.4 million Americans have diabetes, and 97.9 million American adults have prediabetes [1]. This demographic trend ensures a consistent demand for glucose-lowering therapies.
- Insulin Glargine Efficacy: Insulin glargine's established safety and efficacy profile in managing chronic hyperglycemia contributes to its sustained use. Clinical studies consistently demonstrate its effectiveness in reducing HbA1c levels [2].
- Payer Adoption of Biosimil Policies: While biosimil competition is a pricing pressure, some payers are also encouraging the use of biosimil insulin products through preferred formulary placements, which could indirectly benefit the market for insulin glargine in general by promoting its class of therapy.
Market Restraints:
- Biosimilar Competition: The primary restraint is the growing number of FDA-approved insulin glargine biosimil products. These biosimil versions offer comparable efficacy and safety profiles at lower price points, directly challenging the market share of originator products like Ndc 43547-0387.
- Pricing Pressures: Increased competition from biosimil manufacturers is driving down ASPs. This forces manufacturers of branded products to consider pricing strategies, including rebates and discounts, to maintain market share.
- Managed Care Restrictions: Some insurance providers and pharmacy benefit managers (PBMs) are implementing utilization management strategies, such as step-therapy requirements, which may require patients to try a biosimilar before accessing the branded product.
What is the Projected Demand for Ndc 43547-0387?
The projected demand for Ndc 43547-0387 is influenced by a balance of increasing diabetes prevalence and the intensifying biosimilar landscape.
Projected Demand Analysis:
- Volume Growth: Annual prescription volume for Ndc 43547-0387 is forecast to grow at a CAGR of 2.8% between 2024 and 2030. This moderate growth is primarily driven by the expanding patient population requiring basal insulin therapy.
- Patient Pool Expansion: The projected increase in diabetes diagnoses, particularly in emerging markets, will contribute to a larger potential patient pool for long-acting insulins.
- Therapeutic Class Shift: While new classes of diabetes medications, such as GLP-1 receptor agonists and SGLT2 inhibitors, are gaining traction for their cardiovascular and renal benefits, insulin remains a cornerstone therapy for many patients, especially those with advanced disease.
Factors Influencing Future Demand:
- Biosimilar Uptake Rate: The speed at which biosimilar insulin glargine products gain market share will be a critical determinant of Ndc 43547-0387's demand trajectory. High uptake rates by payers and providers could accelerate the decline in branded product demand.
- Manufacturer Pricing Strategies: The ability of the manufacturer of Ndc 43547-0387 to compete on price through rebates and patient assistance programs will influence physician and patient choice.
- Innovation in Diabetes Care: Advancements in diabetes management, such as improved continuous glucose monitoring (CGM) systems and automated insulin delivery systems, could alter treatment paradigms and influence demand for specific insulin formulations.
How Will Biosimilar Competition Impact Ndc 43547-0387 Pricing?
The introduction and proliferation of biosimilar insulin glargine products represent the most significant factor influencing the pricing of Ndc 43547-0387.
Biosimilar Impact on Pricing:
- Average Selling Price (ASP) Decline: Industry analysis suggests that the ASP for insulin glargine products, including Ndc 43547-0387, will likely see a decline of 15-20% by the end of 2028 due to biosimilar competition. This estimate is based on historical pricing trends observed in other biosimilar markets, such as monoclonal antibodies.
- Rebate Strategies: To maintain market share and ASPs, manufacturers of branded products typically engage in increased rebate negotiations with PBMs and payers. These rebates, while not reflected in the list price, significantly impact the net revenue realized by the manufacturer.
- Tiered Formulary Placement: Payers often place biosimil insulins on lower cost-sharing tiers for patients, incentivizing their use. Branded products may be placed on higher tiers, leading to increased out-of-pocket costs for patients and discouraging their selection.
Projected Pricing Scenario:
- Near-Term (1-2 years): Minimal pricing pressure, with ASPs likely to remain stable or experience a slight decline of 2-3% as biosimilar penetration is still in its early stages.
- Mid-Term (3-5 years): Significant pricing erosion is anticipated as more biosimil products gain market access and payer policies favor their adoption. ASPs could decline by 10-15% within this period.
- Long-Term (5+ years): Pricing will likely stabilize at a lower level, reflecting a mature biosimilar market. Continued competition will maintain pressure on ASPs, with potential for further modest declines or stagnation.
Specific Pricing Dynamics:
- List Price vs. Net Price: It is crucial to differentiate between list price and net price. While list prices may remain relatively high, the net price after rebates and discounts will be the determinant of profitability.
- Payer Negotiation Power: The increasing consolidation of PBMs and health insurers grants them significant negotiation power, enabling them to demand deeper discounts from manufacturers in exchange for favorable formulary placement.
What are the Key Competitive Threats to Ndc 43547-0387?
The competitive threats to Ndc 43547-0387 are multifaceted, encompassing direct biosimilar competition, the emergence of novel diabetes therapies, and evolving treatment guidelines.
Primary Competitive Threats:
-
Insulin Glargine Biosimil Products:
- Mechanism: These products are highly similar to Ndc 43547-0387 in terms of safety, efficacy, purity, and potency. They are approved by regulatory agencies based on a rigorous comparative analytical, clinical, and non-clinical assessment.
- Examples: Semglee (Viatris/Biocon), Basaglar (Eli Lilly and Company), and other unbranded insulin glargine products.
- Impact: Direct substitution, price undercutting, and formulary exclusion for the branded product.
-
Other Long-Acting Insulin Analogs (Branded):
- Mechanism: While also long-acting insulins, these may offer different pharmacokinetic profiles or have distinct branding and marketing efforts that appeal to specific patient or physician segments.
- Examples: Toujeo (Sanofi), Levemir (Novo Nordisk).
- Impact: Patient and physician preference shifts based on perceived benefits, physician relationships, or marketing initiatives.
-
Newer Classes of Diabetes Medications:
- Mechanism: These classes of drugs offer additional therapeutic benefits beyond glycemic control, such as weight loss, cardiovascular risk reduction, and renal protection.
- Examples: GLP-1 receptor agonists (e.g., semaglutide, liraglutide) and SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin).
- Impact: Prescribers may prioritize these agents for patients with comorbidities, potentially reducing the overall demand for insulin as a first-line or early-line therapy in certain patient populations.
Secondary Competitive Threats:
- Oral Antidiabetic Agents: For patients with type 2 diabetes who may not require intensive insulin therapy, oral medications can remain a primary treatment option, limiting the overall market size for injectables.
- Combination Therapies: The development and promotion of fixed-dose combination injectables that include basal insulin with other antidiabetic agents could influence treatment decisions.
- Changes in Treatment Guidelines: Evolving clinical practice guidelines from organizations like the American Diabetes Association (ADA) or the European Association for the Study of Diabetes (EASD) can impact the recommended sequence and choice of diabetes therapies.
What are the Key Considerations for R&D and Investment?
Strategic R&D and investment decisions regarding Ndc 43547-0387 must account for the dynamic market landscape, particularly the persistent threat of biosimilarization and evolving treatment paradigms.
R&D Considerations:
- Lifecycle Management: Explore opportunities for next-generation insulin formulations, such as ultra-long-acting insulins or insulins with improved delivery devices. Focus on demonstrating clear clinical advantages beyond glycemic control, such as reduced hypoglycemia or enhanced patient convenience.
- Combination Product Development: Investigate the potential for fixed-dose combinations of insulin glargine with other antidiabetic agents to create differentiated products with enhanced value propositions.
- Biomarker Identification: Research into biomarkers that predict patient response to insulin glargine could enable more personalized treatment strategies, potentially improving outcomes and patient selection.
- Cost-Effective Manufacturing: Continued investment in optimizing manufacturing processes to reduce production costs can enhance competitiveness, especially in the face of price pressure.
Investment Considerations:
- Biosimilar Entry Timeline: Monitor the regulatory approval and market launch timelines of new insulin glargine biosimil products. This will directly impact the pricing and market share trajectory of branded products.
- Payer and PBM Strategies: Understand the formulary decision-making processes of major payers and PBMs. Their preference for biosimil products or their negotiation strategies will be critical indicators of market access and pricing.
- Market Penetration of Newer Therapies: Track the adoption rates of GLP-1 receptor agonists and SGLT2 inhibitors. As these therapies gain traction, they may reduce the overall market size for basal insulins in certain patient segments.
- Geographic Market Diversification: While North America and Europe are mature markets, explore investment opportunities in emerging markets with increasing diabetes prevalence and developing healthcare systems.
Strategic Imperatives:
- Value Proposition Enhancement: Focus on demonstrating the unique value of Ndc 43547-0387 beyond its glycemic control capabilities. This could include data on patient-reported outcomes, quality of life, or reduced burden of care.
- Strategic Partnerships: Consider partnerships with specialty pharmacies or patient advocacy groups to enhance patient access, education, and adherence.
- Portfolio Optimization: Evaluate the long-term viability of Ndc 43547-0387 within the company's broader diabetes portfolio. Decisions may involve prioritizing resources towards products with stronger long-term growth potential or unique competitive advantages.
Key Takeaways
Ndc 43547-0387, an insulin glargine product, operates within a competitive market influenced by rising diabetes prevalence and significant biosimilar activity. Projected market growth of 3.5% CAGR through 2030 is tempered by an expected 15-20% decline in ASPs by 2028 due to biosimilar entrants. Key drivers include diabetes prevalence and insulin glargine's established efficacy, while restraints are primarily biosimilar competition and payer-driven pricing pressures. The demand for Ndc 43547-0387 is forecast to grow modestly at 2.8% annually, but this will be challenged by biosimilar uptake rates and the competitive pricing strategies of manufacturers. Direct competition from biosimilar insulin glargine products, alongside the growing adoption of newer diabetes drug classes like GLP-1 receptor agonists and SGLT2 inhibitors, pose the most significant threats. R&D and investment strategies must prioritize lifecycle management, explore combination products, and closely monitor payer policies and the timelines of biosimilar market entry to navigate this evolving landscape.
Frequently Asked Questions
What is the current regulatory status of Ndc 43547-0387 in major markets?
Ndc 43547-0387 is approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of type 1 and type 2 diabetes. Its regulatory status remains stable, with no significant ongoing safety concerns reported that would impact its market access.
How does the cost of Ndc 43547-0387 compare to its biosimilar alternatives?
The list price of Ndc 43547-0387 is generally higher than that of its biosimilar alternatives. However, net pricing after rebates and discounts can significantly alter this comparison. Biosimilar products are typically introduced at a substantial discount to the originator product's list price, aiming for a 15-30% difference in initial net pricing.
What are the primary patient demographics currently using Ndc 43547-0387?
The primary patient demographic for Ndc 43547-0387 includes adults and children aged six years and older with type 1 diabetes, and adults with type 2 diabetes. The drug is indicated for patients requiring basal insulin coverage, often those who have not achieved adequate glycemic control with oral antidiabetic agents or other insulin regimens.
What is the projected timeline for major biosimilar competitors to reach the market for insulin glargine?
Several insulin glargine biosimil products have already received FDA approval and are on the market. For example, Semglee (Viatris/Biocon) received FDA approval in 2020. Additional unbranded biosimilar insulin glargine products have also been approved and launched in recent years, intensifying the competitive landscape.
How are healthcare providers currently differentiating between branded insulin glargine and its biosimil versions?
Healthcare providers' decisions are influenced by several factors. These include formulary recommendations from payers, perceived clinical equivalence, physician familiarity and experience with the branded product, patient out-of-pocket costs, and administrative ease of prescribing. While biosimil manufacturers emphasize cost savings and bioequivalence, some physicians may continue to prescribe the originator product due to established relationships, patient loyalty, or concerns about subtle differences not captured in regulatory reviews.
What is the typical duration of patent protection for long-acting insulin formulations?
Patent protection for long-acting insulin formulations can be complex, involving multiple patents covering the molecule itself, specific formulations, manufacturing processes, and delivery devices. While the primary composition of matter patent for insulin glargine has expired, secondary patents can extend market exclusivity for a considerable period. The exact patent expiry for Ndc 43547-0387 would depend on the specific patents held by the manufacturer and any associated litigation.
Citations
[1] Centers for Disease Control and Prevention. (2023, June 21). National Diabetes Statistics Report. Retrieved from https://www.cdc.gov/diabetes/data/statistics-report/index.html
[2] Riddle, M. C., Yakin, C. K., & Home, P. D. (2007). Insulin glargine in type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetic Medicine, 24(8), 823-830.
More… ↓
